XML 83 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Debt - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]      
Maturity date Oct. 11, 2024    
Amortization of debt issuance costs and discounts $ 3,000,000.0 $ 3,000,000.0 $ 3,000,000.0
Line of credit fixed fronting fee percentage   0.125%  
Principal balance 0 $ 0  
Letter of Credit      
Debt Instrument [Line Items]      
Line of credit 9,200,000 $ 9,200,000  
Decrease of letter of credit 900,000    
Revolving Credit Facility      
Debt Instrument [Line Items]      
Line of credit 100,000,000.0    
First Lien Credit Agreement      
Debt Instrument [Line Items]      
Line of credit $ 700,000,000.0    
Effective interest rate 5.02% 3.40% 3.97%
Frequency of interest payment quarterly    
Maturity date Oct. 10, 2025    
Description of payments The First Lien Term Loan Facility requires quarterly principal payments through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025    
Covenant terms As of December 31, 2022, we were subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Term Loan Facility. Additionally, GoodRx is restricted from making dividend payments, loans or advances to us. At December 31, 2022, we were in compliance with our covenants    
First Lien Credit Agreement | GoodRx, Inc.      
Debt Instrument [Line Items]      
Percentage of collateralized assets 100.00%    
First Lien Credit Agreement | Minimum      
Debt Instrument [Line Items]      
Interest rate on used amounts 2.75%    
Maximum net leverage ratio 8.20%    
Interest rate on used amounts 2.50%    
Interest rate on unused amounts 0.25%    
First Lien Credit Agreement | Maximum      
Debt Instrument [Line Items]      
Interest rate on used amounts 3.00%    
Maximum net leverage ratio 1.00%    
Interest rate on unused amounts 0.50%